Dassault Systèmes has completed its $1.8 billion cash acquisition of ArisGlobal, uniting its life sciences brands into a single AI-native platform. Why it matters: one of the largest life-sciences software deals of the year puts regulatory, safety, clinical, and discovery data under one AI roof.
October 29, 2026
What happened
Dassault Systèmes announced on October 28, 2026, from Vélizy-Villacoublay, France, that the ArisGlobal acquisition has closed. The price was $1.8 billion in cash at closing, with up to $200 million in additional consideration tied to multi-year AI-related revenue milestones.
ArisGlobal’s platform covers regulatory, safety, quality, and medical affairs, and serves as a single source of truth for more than 200 clients, including half of the top 50 global biopharma companies, according to Dassault. ArisGlobal will continue to be led by Aman Wasan as CEO.
What Dassault is building
The company is bringing ArisGlobal together with its existing BIOVIA and MEDIDATA brands in what it calls 3D UNIV+RSES: one AI-native enterprise platform connecting scientific discovery, clinical development, manufacturing, and real-world patient outcomes in a continuous cycle. Dassault says MEDIDATA has been used across 42,000 trials and 13 million patients, and BIOVIA pioneered modeling and simulation in science.
To run the combined business, Dassault appointed Dr. Ashwini Zenooz as Executive Vice President and CEO of its Life Sciences and Healthcare sector, and as a member of the Executive Committee, reporting to Pascal Daloz. Zenooz will lead MEDIDATA, BIOVIA, and ArisGlobal, with responsibility for strategy, integration, go-to-market, and sales, as well as partnerships across pharma, biotech, medtech, diagnostics, and digital health. She previously held leadership roles at Salesforce, Commure, and the U.S. Department of Veterans Affairs, and is a fellowship-trained radiologist.
Why it matters
Drug development has long run as separate worlds — discovery, trials, manufacturing, and patient outcomes each learning slowly from the others, in Dassault’s own framing. The bet behind this deal is that AI only helps if it can see across all of them at once, with the regulatory and safety record attached. Whether that works depends on integration, not announcements: three brands, three product histories, and highly regulated customer data. For buyers in biopharma, the practical question to ask Dassault now is what changes in their existing MEDIDATA, BIOVIA, or ArisGlobal contracts, and what the unified platform actually ships, and when.
Frequently asked questions
How much did Dassault Systèmes pay for ArisGlobal?
$1.8 billion in cash at closing, plus up to $200 million more tied to multi-year AI-related revenue milestones.
Who will lead Dassault’s Life Sciences and Healthcare sector?
Dr. Ashwini Zenooz, appointed Executive Vice President and CEO of the sector. ArisGlobal itself continues to be led by Aman Wasan.
Which brands are being united in the platform?
ArisGlobal joins BIOVIA and MEDIDATA in a single AI-native platform covering discovery, clinical development, manufacturing, and patient outcomes.
Sources: Dassault Systèmes, Engineering.com